)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
VolitionRX
VolitionRX (VNRX) investor relations material
VolitionRX Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary10 Sep, 2026
Recent achievements
Cat paper submitted; $5M milestone payment expected if published; Fujifilm Vet Systems launch on automated i10 platform.
Expansion into non-sepsis disease areas and Mayo Clinic publication in trauma; automated platform installation in Q3 2026.
Demonstrated utility of rapid, point-of-care finger-prick test in sepsis patients; DETECSEPS on track to launch Q3.
Certification completed at three French hospitals; manuscripts submitted for peer review and available as preprints.
Co-marketing agreement in place with Hologic; larger scale programs in confidential discussions.
Executive summary and business model
Mission to save lives and improve outcomes for people and animals worldwide.
Focus on licensing IP in cancer and sepsis, with low-cost testing and commercial animal health products.
$23M in licensing, $1.4M revenue in H1 2026, and 51 patent families as of June 2026.
Asset-light, platform-agnostic approach; no need for proprietary machines, labs, or sales reps.
Low capex, low opex business model centered on commercial partnerships and out-licensing.
Technology and product pipeline
Expertise in quantifying nucleosomes and working at the cutting edge of epigenetics.
Multiple products launched: Nu.Q Vet, Nu.Q Nets, Nu.Q Cancer, Capture Seq, and Nu.Q Discover.
Nu.Q Cancer targets $4B TAM, Nu.Q Nets >$3B ICU/ED, Capture Seq $23B, Nu.Q Vet $170M.
World-first isolation of 99% pure tumor-associated DNA from liquid biopsy; novel biomarkers and proof-of-concept clinical data.
Rapid, point-of-care finger-prick test for sepsis patients expands use cases and access in low-income countries.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from VolitionRX
- Over 10 million shares registered for resale, raising dilution and financial risk concerns.VNRX
Registration filing - Amendment updates selling stockholder table for 10M+ shares offered by Lind, with adjusted terms.VNRXRegistration filing
- Up to 10 million shares registered for resale could cause significant dilution and price pressure.VNRXRegistration filing
- Expansion into new disease areas and global licensing drive growth, with clinical adoption expected in 2026.VNRXCorporate presentation
- Asset-light, licensing-driven growth targets multi-billion dollar diagnostics markets with strong IP.VNRXCorporate presentation
- First half 2026 revenue up 112% with major clinical, licensing, and cost reduction progress.VNRXQ2 2026
- Platform-agnostic diagnostics and licensing drive growth in cancer, sepsis, and animal health.VNRXCorporate presentation
- 3.3 million shares registered for resale by a noteholder, with no proceeds to the company.VNRXRegistration filing
- Nu.Q blood tests enable rapid, cost-effective cancer detection and monitoring worldwide.VNRXStudy update
Next VolitionRX earnings date
Q3 202613 Nov, 2026
VolitionRX
Next VolitionRX earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
VolitionRX Ltd is a multi-national epigenetics company that specializes in the development of blood tests through its proprietary Nucleosomics™ platform. This platform is designed to create simple, easy-to-use, and cost-effective blood tests aimed at diagnosing and monitoring a variety of life-altering diseases, including some cancers and diseases related to NETosis, such as sepsis and COVID-19. The company is headquartered in Henderson, Nevada, and its shares are listed on the NYSE American under the ticker symbol VNRX.